WO2005016315A1 - Compositions pharmaceutiques de nateglinide - Google Patents

Compositions pharmaceutiques de nateglinide Download PDF

Info

Publication number
WO2005016315A1
WO2005016315A1 PCT/IB2004/002654 IB2004002654W WO2005016315A1 WO 2005016315 A1 WO2005016315 A1 WO 2005016315A1 IB 2004002654 W IB2004002654 W IB 2004002654W WO 2005016315 A1 WO2005016315 A1 WO 2005016315A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
oral pharmaceutical
composition according
nateglinide
water
Prior art date
Application number
PCT/IB2004/002654
Other languages
English (en)
Inventor
Romi Barat Singh
Anu Shilpa
Vishnubhotla Nagaprasad
Sanjeev Kumar Sethi
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2005016315A1 publication Critical patent/WO2005016315A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to pharmaceutical compositions of nateglinide with 50-70% of water-soluble filler alone or in combination with a channeling agent.
  • Nateglinide is an amino acid derivative that lowers blood glucose levels by stimulating insulin secretion from the pancreas. It is widely indicated as monotherapy to lower blood glucose in patients with Type 2 diabetes. It is also indicated for use in combination with Metformin. Nateglinide oral tablets are commercially available in 60 mg and 120 mg strengths and are marketed by Novartis under the trade name STARLIX®.
  • the active agent nateglinide is described in EP 196222 and EP 526171.
  • the active drug substance includes pharmaceutically acceptable acid addition salts, for example, sodium, maleate or hydrochloride.
  • U.S. Patent No. 6,559,188 discloses particular pharmaceutical compositions of nateglinide.
  • the pharmaceutical compositions disclosed include water-soluble lactose and water-insoluble microcrystalline cellulose as fillers. Lactose is present at a concentration of 34% to 36% w/w and microcrystalline cellulose is present at a concentration of 17%) to 23%) w/w, with the total concentration of filler (water-soluble and water-insoluble combined) ranging from 50-70% w/w.
  • nateglinide tablets when prepared with water-soluble filler alone at a concentration of 50-70% w/w, show a dissolution profile wherein at least 70%) of the drug is released within 45 minutes. Further, we have also discovered that use of at least one channeling agent in the core along with the water- soluble filler improves dissolution.
  • an oral pharmaceutical composition that includes nateglinide or pharmaceutically acceptable salts thereof and a water-soluble filler at a concentration range of 50-70%>w/w of the composition.
  • the oral pharmaceutical composition may have a dissolution profile wherein at least 70% ⁇ by weight of the nateglinide is released within 45 minutes in 1000 ml, 0.01 N HC1, with 0.5% SLS (pH- 1.2), using USP apparatus - II, at 50 rpm.
  • Embodiments of the pharmaceutical composition may include one or more of the following features.
  • the water-soluble filler may be one or more of lactose, white sugar, sucrose, glucose, sorbitol and mixtures thereof and in particular may be lactose.
  • the oral pharmaceutical composition may further include one or more pharmaceutically acceptable excipients.
  • the pharmaceutical composition may include one or more of binders, disintegrants, lubricants, and coloring and flavoring agents.
  • the binder may be one or more of methyl cellulose, hydroxypropyl cellulose, hydroxy propyl methyl cellulose, povidone, gelatin, gum Arabic, ethyl cellulose, polyvinyl alcohol, pullulan, pregelatinized starch, agar, tragacanth, sodium alginate, propylene glycol, and mixtures thereof.
  • the binder may be povidone.
  • the disintegrant may be one or more of starch, croscarmellose sodium, crospovidone, sodium starch glycolate, polacrillin potassium and mixtures thereof.
  • the disintegrant may be croscarmellose sodium.
  • the lubricant may be one or more of colloidal anhydrous silica, stearic acid, magnesium stearate, calcium stearate, talc, hydrogenated castor oil, sucrose esters of fatty acids, microcrystalline wax, yellow beeswax, and white beeswax.
  • the lubricant may be magnesium stearate.
  • the oral pharmaceutical composition may be a tablet or capsule. The tablet may be coated with one or more functional and/or non- functional layers.
  • the oral pharmaceutical composition may further include one or more channeling agents.
  • the channeling agent may be one or more of a sugar, a salt, a sugar alcohol, or combinations thereof.
  • the sugar may be one or more of compressible sugar, glucose, and mannose.
  • the salt may be one or more of sodium chloride and potassium chloride.
  • the sugar alcohol may be one or more of mannitol, sorbitol, xylitol, erythritol, lactitol, and maltitol.
  • the channeling agent may be compressible sugar or it may be sodium chloride.
  • the process includes blending nateglinide, disintegrant, and a water-soluble filler to form a blend; granulating the blend with a binder solution; drying and sizing the granules; and lubricating and compressing the lubricated granules to form an oral pharmaceutical composition.
  • the water-soluble filler is present at a concentration of 50% to 70%> w/w of the oral pharmaceutical composition.
  • the process may further include blending a channeling agent with the nateglinide, disintegrant, and water soluble filler to form a blend.
  • the granulation may be wet granulation or dry granulation.
  • the binder solution may include a binder and a solvent.
  • the solvent may be one or more of methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, and water.
  • Embodiments of the process for the preparation of an oral pharmaceutical composition may include one or more pharmaceutically acceptable excipients.
  • the pharmaceutical excipients maybe one or more of binders, disintegrants, lubricants, coloring and flavoring agents.
  • a method for the treatment of metabolic disorders, type 2 diabetes mellitus, or a disease or condition associated with diabetes mellitus includes administering to a patient in need thereof a pharmaceutical composition of nateglinide.
  • the pharmaceutical composition includes nateglinide or pharmaceutically acceptable salts thereof, and a water-soluble filler in a concentration range of 50-70%w/w of the composition.
  • the pharmaceutical composition administered may further include a channeling agent.
  • the pharmaceutical composition administered may have a dissolution profile wherein at least 70% > by weight of the nateglinide is released within 45 minutes in 1000 ml, 0.01 N HC1, with 0.5% SLS (pH-1.2), using USP apparatus - II, at 50 rpm.
  • the term 'nateglinide' as used herein includes nateglinide in a free or pharmaceutically acceptable acid addition salt, for example as a sodium or maleate salt.
  • the composition includes the B- or H-type crystal modification of nateglinide, and in some particular embodiments the H-type.
  • the active ingredient or a pharmaceutically acceptable salt thereof may also be used in the form of a hydrate or may include other solvents used for crystallization.
  • the dosage range of the nateglinide depends upon factors known to the person skilled in the art including body weight, age, the nature and severity of the condition to be treated, and the mode of administration to be employed. Unless stated otherwise herein, nateglinide is preferably divided and administered one to four times per day.
  • Nateglinide can be administered in the dosage range of about 5 mg/day to about 1200 mg/day, for example about 10 mg/day to about 1000 mg/day or for example about 25 mg/day to about 800 mg/day.
  • 'Channeling agents' as used herein include water-soluble excipients, which can be solubilized in water or gastrointestinal fluid, thus forming channels through which the water or the gastrointestinal fluid enters the formulation. This action aids in improving dissolution.
  • Suitable channeling agents include one or more of a sugar, for example compressible sugar, glucose, or mannose; a salt selected from sodium chloride, or potassium chloride; a sugar alcohol, for example mannitol, sorbitol, xylitol, erythritol, lactitol, or maltitol; or a mixture thereof.
  • a sugar alcohol for example mannitol, sorbitol, xylitol, erythritol, lactitol, or maltitol
  • Suitable pharmaceutically acceptable excipients include one or more of fillers, binders, disintegrants, lubricants, glidants, and colors.
  • Suitable fillers include one or more of corn starch, lactose, white sugar, sucrose, glucose, sorbitol, calcium carbonate, calcium phosphate-dibasic, calcium phosphate- tribasic, calcium sulfate, microcrystalline cellulose, sihcified microcrystalline cellulose, cellulose powdered, dextrates, dextrins, dextrose, fructose, kaolin, lactitol, mannitol, sorbitol, starch, and pregelatinized starch.
  • Suitable binders include one or more of methyl cellulose, hydroxypropyl cellulose, hydroxy propyl methyl cellulose, polyvinylpyrrolidone, gelatin, gum Arabic, ethyl cellulose, polyvinyl alcohol, puUulan, pregelatinized starch, agar, tragacanth, sodium alginate, and propylene glycol.
  • Suitable disintegrants include one or more of starch, croscarmellose sodium, crospovidone, polacrillin potassium, sodium and starch glycolate.
  • Suitable lubricants and glidants include one or more of colloidal anhydrous silica, stearic acid, magnesium stearate, calcium stearate, talc, hydro genated castor oil, sucrose esters of fatty acids, microcrystalline wax, yellow beeswax, and white beeswax.
  • Suitable coloring agents include any FDA approved colors for oral use. Nateglinide or a pharmaceutically acceptable salt thereof may be present in any amount which is sufficient to elicit a therapeutic effect and, where applicable, may be present either substantially in the form of one optically pure enantiomer or as a mixture, racemic or otherwise, of enantiomers.
  • Nateglinide may be present in an amount of about 5% to about 70%> w/w, for example about 15%> to about 40%> w/w, based on the total weight of the dry composition.
  • Water-soluble filler may be present in an amount of about 50% to about 70%> w/w by weight based on the total weight of the dry composition.
  • the channeling agents may be present in an amount of about 5% to about 30% w/w, for example about 10% to about 25%> w/w, based on the total weight of the dry composition.
  • the solid dose formulation can be prepared by processes known in the art including one or more of wet granulation, dry granulation and direct compression and may be in the form of tablet or capsule.
  • the nateglinide tablet may be prepared by blending nateglinide and one or more water-soluble fillers, optionally a channeling agent, and disintegrant; granulating the blend with a binder solution; drying the granules; sizing; and lubricating and compressing the lubricated granules.
  • nateglinide tablets may be prepared by blending nateglinide, water-soluble filler, optionally a chaiineling agent, disintegrant and binder; granulating the blend with a solvent; drying the granules; sizing; and lubricating and compressing the lubricated granules.
  • Granulation may be carried out in fluidized bed dryer and sizing can be done by milling or pulverization.
  • the nateglinide tablet may be prepared by blending nateglinide, water-soluble filler, optionally a channeling agent, disintegrant and binder; compacting or slugging the blend; breaking the slugs to make granules; and lubricating and compressing the lubricated granules.
  • the nateglinide tablet may be prepared by blending nateglinide, water-soluble filler, optionally a channeling agent, disintegrant, binder and lubricant; and compressing.
  • the tablets prepared by the present invention may be coated with one or more additional layers including film-forming agents and/or pharmaceutically acceptable excipients.
  • the coating layers over the tablet may be applied as a solution/dispersion of coating ingredients using any conventional technique known in the prior art including spray coating in a conventional coating pan or fluidized bed processor, and dip coating.
  • Suitable solvents used for preparing a solution/dispersion of the coating ingredients include one or more of methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, water and the like, and mixtures thereof.
  • Suitable film forming agents include one or more of ethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methyl cellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropyl methyl phthalate, cellulose acetate, cellulose acetate trimelliatate, cellulose acetate phthalate; waxes such as polyethylene glycol; methacrylic acid polymers such as Eudragit ® RL and RS; and the like and mixture thereof.
  • commercially available coating compositions comprising film-forming polymers marketed under various trade names, for example Opadry® may also be used for coating.
  • the following examples further exemplify the invention and do not limit the scope of the invention.
  • Nateglinide 120mg after potency and moisture adjustment PROCEDURE 1. Nateglinide along with lactose, povidone, colloidal silicon dioxide and croscarmellose sodium are mixed in a high shear mixer and granulated using purified water. 2. The wet granules are dried in a fluid bed drier, passed through a screen and then subjected to sizing. 3. The extragranular colloidal silicon dioxide and croscarmellose sodium are mixed, passed through a screen and blended with the granules of step 2. 4. The magnesium stearate is passed through a screen, blended with the blend of step 3 and the total mixture is compressed to tablets. EXAMPLE 2
  • Nateglinide 120mg after potency and moisture adjustment PROCEDURE 1. Nateglinide along with lactose, sodium chloride, povidone, colloidal silicon dioxide and croscarmellose sodium are mixed in a high shear mixer and granulated using purified water. 2. The wet granules are dried in a fluid bed drier, passed through a screen and then subjected to sizing. 3. The extragranular colloidal silicon dioxide and croscarmellose sodium are mixed, passed through a screen and blended with the granules of step 2. 4. The magnesium stearate is passed through a screen, blended with the blend of step 3 and the total mixture is compressed to tablets. EXAMPLE 3
  • Nateglinide 120mg after potency and moisture adjustment PROCEDURE 1. Nateglinide along with lactose, compressible sugar, povidone, colloidal silicon dioxide and croscarmellose sodium are mixed in a high shear mixer and granulated using purified water. 2. The wet granules are dried in a fluid bed drier, passed through a screen and then subjected to sizing. 3. The extragranular colloidal silicon dioxide and croscarmellose sodium are mixed, passed through a screen and blended with the granules of step 2. 4. The magnesium stearate is passed through a screen, blended with the blend of step and the total mixture is compressed to tablets.
  • Table 1 indicates that compositions containing water-soluble filler alone (Example

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques de Natéglinide contenant 50-70 % d'une charge hydrosoluble seule ou en association avec un agent d'acheminement. Ces compositions peuvent présenter un profil de dissolution dans lequel au moins 70 % en poids de Natéglinide est libéré dans un délai de 45 minutes.
PCT/IB2004/002654 2003-08-14 2004-08-13 Compositions pharmaceutiques de nateglinide WO2005016315A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1003/DEL/2003 2003-08-14
IN1003DE2003 2003-08-14
IN1445DE2003 2003-11-21
IN1445/DEL/2003 2003-11-21

Publications (1)

Publication Number Publication Date
WO2005016315A1 true WO2005016315A1 (fr) 2005-02-24

Family

ID=34196284

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/002654 WO2005016315A1 (fr) 2003-08-14 2004-08-13 Compositions pharmaceutiques de nateglinide

Country Status (1)

Country Link
WO (1) WO2005016315A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006013444A1 (fr) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Preparations de compositions pharmaceutiques stables de nateglinide et procedes de preparation de celles-ci
US10568839B2 (en) 2011-01-11 2020-02-25 Capsugel Belgium Nv Hard capsules
US11319566B2 (en) 2017-04-14 2022-05-03 Capsugel Belgium Nv Process for making pullulan
US11576870B2 (en) 2017-04-14 2023-02-14 Capsugel Belgium Nv Pullulan capsules

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0965339A1 (fr) * 1996-11-15 1999-12-22 Ajinomoto Co., Inc. Preparation en comprimes
EP1258249A1 (fr) * 1999-12-28 2002-11-20 Ajinomoto Co., Inc. Preparations orales pour diabetes
US20030036479A1 (en) * 2001-05-11 2003-02-20 Eastman Kodak Company Antistat of onium salt and polyether polymer
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
WO2003076393A1 (fr) * 2002-03-11 2003-09-18 Novartis Ag Sels de nateglinide

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0965339A1 (fr) * 1996-11-15 1999-12-22 Ajinomoto Co., Inc. Preparation en comprimes
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
EP1258249A1 (fr) * 1999-12-28 2002-11-20 Ajinomoto Co., Inc. Preparations orales pour diabetes
US20030036479A1 (en) * 2001-05-11 2003-02-20 Eastman Kodak Company Antistat of onium salt and polyether polymer
WO2003076393A1 (fr) * 2002-03-11 2003-09-18 Novartis Ag Sels de nateglinide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HE XIAO-RONG, HU XIN, YAN XIAO-YAN: "dissolution study of tablets of nateglinide", CHIN HOSP PHARM J, vol. 23, no. 2, February 2003 (2003-02-01), pages 82-84, XP001204565 *
XU WEI, YIN LI-FANG: "Preparation and quality investigation of nateglinide dispersible tablets", ACADEMIC JOURNAL OF GUANGDONG COLLEGE OF PHARMACY, vol. 19, no. 1, March 2003 (2003-03-01), pages 3 - 6, XP001204563 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006013444A1 (fr) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Preparations de compositions pharmaceutiques stables de nateglinide et procedes de preparation de celles-ci
US10568839B2 (en) 2011-01-11 2020-02-25 Capsugel Belgium Nv Hard capsules
US11319566B2 (en) 2017-04-14 2022-05-03 Capsugel Belgium Nv Process for making pullulan
US11576870B2 (en) 2017-04-14 2023-02-14 Capsugel Belgium Nv Pullulan capsules
US11878079B2 (en) 2017-04-14 2024-01-23 Capsugel Belgium Nv Pullulan capsules

Similar Documents

Publication Publication Date Title
US10441585B2 (en) Formulations containing nalbuphine and uses thereof
JP4948691B2 (ja) 舌下又は頬投与によって送達される薬物の徐放
US7741374B1 (en) Methods of use of fenofibric acid
RU2376988C2 (ru) Фармацевтические композиции замедленного высвобождения, содержащие аплиндор и его производные
KR101840182B1 (ko) 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일]-1ｈ-퀴놀린-2-온 락테이트 일수화물을 포함한 제약 조성물
CA2740146A1 (fr) Formes posologiques a liberation immediate d'oxybate de sodium
JP2008526733A (ja) 糖尿病治療剤の経口投与用徐放性複合製剤及びその製造方法
JPWO2005055989A1 (ja) 薬物含有粒子および該粒子を含む固形製剤
ZA200501541B (en) Bicifadine formulation
US20110196032A1 (en) Pharmaceutical Dosage Form of an Antidepressant
KR102479497B1 (ko) 바레니클린 서방성 제제 및 이의 제조 방법
US20070219250A1 (en) Pharmaceutical Compositions of Nateglinide
WO2006123213A1 (fr) Preparations a liberation modifiee de gliclazide
CA2853117C (fr) Composition pharmaceutique sublinguale contenant un antihistaminique et procede de preparation associe
WO2003082261A1 (fr) Formulations de venlafaxine a liberation prolongee
WO2005016315A1 (fr) Compositions pharmaceutiques de nateglinide
EP3886817A1 (fr) Composition pharmaceutique comprenant du ramipril et de l'indapamide
US20100008956A1 (en) Composition and combinations of carboxylic acid losartan in dosage forms
EP1776102A1 (fr) Preparations de compositions pharmaceutiques stables de nateglinide et procedes de preparation de celles-ci
WO2005092319A1 (fr) Compositions pharmaceutiques a desintegration rapide, comprenant du nateglinide et un delitant
KR20160141044A (ko) 실데나필 제어방출성 경구제제
KR20160141045A (ko) 보센탄을 함유한 약학적 조성물
US20160263102A1 (en) Pharmaceutical composition of bupropion and naltrexone
KR100509886B1 (ko) 염산온단세트론을 함유하는 속붕해성 정제의 조성물 및 그제조방법
BR102022001244A2 (pt) Composição farmacêutica de liberação modificada de ácido tranexâmico e comprimido de camada dupla

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1423/DELNP/2006

Country of ref document: IN

122 Ep: pct application non-entry in european phase